Skip to search formSkip to main contentSkip to account menu

Anti-Met Monoclonal Antibody Mixture Sym015

Known as: Sym-015, Hu9006-Hu9338, Hu9006/Hu9338 
A mixture of two humanized immunoglobulin G1 (IgG1) monoclonal antibodies, Hu9006 and Hu9338, which recognize non-overlapping epitopes in the… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 810: Anti-tumor effects of Sym015 in HGF overexpressing gastric cancer cell lines
MET, hepatocyte growth factor receptor (HGFR), has received considerable attention as a potential target for cancer therapy. MET… 
2017
2017
Abstract 27: Combination of paclitaxel and Sym015, a mixture of two monoclonal antibodies directed at MET receptor, to increase anti-tumor effects in gastric cancer
MET is a proto-oncogene that encodes a protein known as hepatocyte growth factor receptor (HGFR), involved in proliferative… 
2016
2016
Abstract 1218: A novel synergistic antibody pair targeting non-overlapping epitopes of MET effectively inhibits MET-driven cancer models
The receptor tyrosine kinase MET (Hepatocyte Growth Factor Receptor, HGFR) has been associated with development and progression… 
2016
2016
Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody
The tyrosine kinase receptor MET is involved in progression of a variety of human cancers and constitutes a promising therapeutic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)